Active Recombinant Full Length Human PLK1 Protein, DDK-tagged, Biotinylated

• Cat.No.: PLK1-5411HF
• Product Overview: Full-length human PLK1 [1-603(end) amino acids of accession number NP_005021.2] was expressed as N-terminal DYKDDDDK tagged, biotinylated protein (72 kDa) using baculovirus expression system. The protein was purified by using DYKDDDDK tag antibody agarose.

Specification

• Source: Insect (sf21)
• Species: Human
• Tag: DDK
• Form: 50 mM Tris-HCl, 150 mM NaCl, 0.05% Brij35, 1 mM DTT, 10% glycerol, pH7.5
• Bio-activity: The activity was measured by off-chip mobility shift assay. The enzyme was incubated with fluorecence-labeled substrate and Mg(or Mn)/ATP. The phosphorylated and unphosphorylated substrates were separated and detected by LabChip™3000.
• Protein length: 1-603(end)
• Purity: 89%
• Applications: SDS-PAGE
• Storage: Store at -80C. Avoid repeating freeze-thaws.

Gene Information

• Gene Name: polo-like kinase 1
• Official Symbol: PLK1
• Synonyms: PLK1;PLK;STPK13
• Protein Refseq: NP_005021.2
• UniProt ID: P53350

Reviews

09/14/2022

the manufacturer's dedication to continuous improvement and innovation is evident in their ongoing efforts to enhance the PLK1 protein's performance and optimize its applications.

02/26/2017

The exceptional quality and reliability of the PLK1 protein provided by the manufacturer cannot be overstated.

03/09/2016

Its purity and consistency guarantee accurate and consistent results, allowing for confident data interpretation and analysis.

Q&As

How can PLK1 inhibitors be used in combination with other cancer treatments?

PLK1 inhibitors can be combined with chemotherapy or radiation therapy to enhance their effectiveness in treating certain types of cancer.

What are the potential clinical applications of PLK1 inhibitors in cancer treatment?

PLK1 inhibitors are being investigated as potential cancer therapies to target and inhibit the overactive PLK1 in cancer cells.

Are there any specific cancer types where PLK1 inhibitors have shown promise in clinical trials?

PLK1 inhibitors have shown promise in clinical trials for various cancer types, including breast, lung, and colorectal cancers.

How do researchers target PLK1 specifically in cancer cells without affecting healthy cells?

This is a significant challenge, and researchers are working on developing selective inhibitors that primarily target cancer cells.

Can PLK1 protein be used as a biomarker for cancer diagnosis?

PLK1 levels can be elevated in some cancers, and its expression can be used as a diagnostic or prognostic biomarker.